You are here: Industry Insights > Seqirus

News List

Seqirus Announces New Facility Supporting R&D of Leading-Edge Influenza Vaccine Technology AmericanPharmaceuticalReview
February 09, 2022
Seqirus, a business of CSL Limited, announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass. The new facility will support the company's growing R&D portfolio...
Study demonstrates safety and efficacy of co-administering COVID-19 and flu vaccines pharmatimes
June 18, 2021
A study conducted by Novavax has found that co-administering a COVID-19 vaccine with a flu vaccine is safe and effective, with the efficacy of both jabs appearing to be preserved.
Cell-based seasonal influenza vaccine safe and effective in children europeanpharmaceuticalreview
May 08, 2021
Phase III data shows Seqirus’ cell-based quadrivalent seasonal influenza vaccine was as effective and safe as an equivalent FDA-approved egg-based vaccine in paediatric patients.
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market americanpharmaceuticalreview
August 06, 2020
Seqirus has begun shipping its portfolio of seasonal influenza vaccines to customers in the U.S. for the 2020/21 influenza season.
Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines americanpharmaceuticalreview
July 16, 2019
Seqirus announced it is first-to-market with shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2019/20 influenza season.
Zambon Announces Approval And Artg Listing Of Safinamide In Australia For Treatment Of Patients With Parkinson’s Disease firstwordpharma
December 02, 2018
Xadago has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal requirement for supply and marketing of the medicine.
Seqirus to spend $140M, add 120 jobs at U.S. plant as it takes cell-based flu vaccines global fiercepharma
November 28, 2018
Seqirus has big plans for its cell-based flu vaccine franchise, and after a scale-up to reach 20 million doses this year, the company still needs more capacity.
Cell-derived flu vaccine strains a better match than eggs, Seqirus analysis finds fiercepharma
November 09, 2018
Flu vaccine efficacy problems were well documented throughout last year’s harsh season. Now the world’s largest cell-based vaccine producer, Seqirus, has published data
Seqirus Receives FDA Approval for New Mfg. Process contractpharma
August 27, 2018
Seqirus announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina. The approval will enable Seqirus to more than double current production levels of FLUCELVAX® QUADRIVALENT for supply in the 2019/20 i
Seqirus joins universal flu vaccine partnership UIVI fiercevaccines
July 23, 2018
The quest for a universal flu vaccine has attracted significant attention as problems with traditional flu shots have grabbed headlines in recent years. Now, leading flu vaccine player Seqirus has teamed up with the Human Vaccines Project's Universal Infl

Previous page 1 2 Next page